/VAXX

VAXX Stock - Vaxxinity, Inc.

Q: What is the analyst price target for VAXX?

Analyst price target information is not currently available for VAXX.

Q: What is VAXX's market cap?

Market capitalization information is not currently available for VAXX.

Healthcare|Biotechnology|OTC

$0.00-20.00%

$0.00 (-20.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for VAXX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.53

52W High$0.06

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	N/A	N/A	$66,000	$557,000	N/A
Gross Profit	$-2,234,000	$-1,684,000	$-1,871,000	$505,000	$-107,000
Gross Margin	N/A	N/A	-2834.8%	90.7%	N/A
Operating Income	$-58,285,000	$-75,979,000	$-125,075,000	$-32,282,000	$-13,661,000
Net Income	$-56,934	$-75,210,000	$-137,175,000	$-39,957,000	$-14,219,000
Net Margin	N/A	N/A	-207840.9%	-7173.6%	N/A
EPS	$-0.00	$-0.60	$-1.09	$-0.32	$-0.11

Company Overview

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

1 Bullish0 Neutral/Bearish

Price Targets

Average Target

↑ 1749900.0% Upside

Now

Low

Average

High

Based on 1 analyst

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
September 8th 2023	Robert W. Baird	Initiation	Outperform	$7
April 27th 2022	Evercore ISI	Initiation	In-line	-

Earnings History & Surprises

VAXX

Beat Rate

64%

Last 11 quarters

Avg Surprise

+0.3%

EPS vs Estimate

Beats / Misses

7/3

1 met exactly

Latest EPS

$-0.15

Q2 2024

EPS Surprise History

Q3 22

+63.2%

$-0.14vs$-0.38

Q4 22

+6.3%

$-0.15vs$-0.16

Q1 23

0.0%

$-0.16vs$-0.16

Q2 23

+6.3%

$-0.15vs$-0.16

Q3 23

+31.3%

$-0.11vs$-0.16

Q4 23

+28.6%

$-0.10vs$-0.14

Q1 24

+30.8%

$-0.09vs$-0.13

Q2 24

-50.0%

$-0.15vs$-0.10

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2025	Jun 5, 2025	—	—	—	—
Q1 2025	Mar 27, 2025	—	—	—	—
Q4 2024	Nov 18, 2024	—	—	—	—
Q3 2024	Sep 30, 2024	—	—	—	—
Q2 2024	May 14, 2024	$-0.10	$-0.15	-50.0%	✗ MISS
Q1 2024	Mar 27, 2024	$-0.13	$-0.09	+30.8%	✓ BEAT
Q4 2023	Nov 8, 2023	$-0.14	$-0.10	+28.6%	✓ BEAT
Q3 2023	Aug 9, 2023	$-0.16	$-0.11	+31.3%	✓ BEAT
Q2 2023	May 9, 2023	$-0.16	$-0.15	+6.3%	✓ BEAT
Q1 2023	Mar 27, 2023	$-0.16	$-0.16	0.0%	= MET
Q4 2022	Nov 10, 2022	$-0.16	$-0.15	+6.3%	✓ BEAT
Q3 2022	Aug 11, 2022	$-0.38	$-0.14	+63.2%	✓ BEAT
Q2 2022	May 9, 2022	$-0.34	$-0.31	+8.8%	✓ BEAT
Q1 2022	Mar 24, 2022	$-0.35	$-0.48	-37.1%	✗ MISS
Q4 2021	Dec 23, 2021	$-0.13	$-0.24	-84.6%	✗ MISS
Q4 2021	Nov 12, 2021	—	$-0.22	—	—
Q1 2021	Mar 31, 2021	—	$-0.26	—	—
Q4 2020	Dec 31, 2020	—	$-0.10	—	—
Q3 2020	Sep 30, 2020	—	$-0.13	—	—
Q2 2020	Jun 30, 2020	—	$-0.06	—	—